Our Company

Guided by Deep
Scientific Expertise &
Driven by a Passion
to Deliver

We are focused on harnessing the power of the TGF-beta superfamily, the target-rich biology behind the body’s remarkable capacity for cellular growth and repair. Our insights and protein engineering capabilities enable us to design first- and best-in-class candidates for serious and rare diseases. Our lead product, luspatercept, is being evaluated in two global Phase 3 trials in partnership with Celgene to treat chronic anemia and associated complications in myelodysplastic syndromes (MDS), beta-thalassemia, and myelofibrosis. We are also advancing clinical programs for neuromuscular and pulmonary diseases.

Read More

A New Approach to Engaging the Body’s Ability to Rebuild and Repair

We Are Building a Rich Pipeline Based on Leadership in TGF-Beta Biology


Hematology

Luspatercept

Hematology

Luspatercept
PreclinicalPhase 1Phase 2Phase 3
 
Myelodysplastic Syndromes
Myelodysplastic
Syndromes
MEDALIST TrialMEDALIST Trial
COMMANDS Trial (Planned)COMMANDS Trial
Long-Term Extension TrialLong-Term Ext Tr
Beta-Thalassemia
Beta-Thalassemia
BELIEVE TrialBELIEVE Trial
Long-Term Extension TrialLong-Term Ext Tr
BEYOND Trial (Planned)BEYOND Trial
Myelofibrosis
Myelofibrosis
Ph2 TrialPh 2


Neuromuscular

ACE-083
PreclinicalPhase 1Phase 2Phase 3

Neuromuscular

ACE-083
FSH Muscular Dystrophy
FSH Muscular Dystrophy
Ph2 Trial (Part 1)Ph2
Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease
Ph2 Trial (Part 1)Ph 2
ACE-2494
Neuromuscular Disease
Neuromuscular Disease
Ph1 Trial (Planned)Ph 1


Pulmonary

Sotatercept
PreclinicalPhase 1Phase 2Phase 3

Pulmonary

Sotatercept
 
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Ph2 Trial (Planned)Ph2 Trial
ACE-1334
Pulmonary Disease
Pulmonary Disease
PreclinicalPreclinical

Acceleron

News